Cutting Edge: Identification of Neutrophil PGLYRP1 as a Ligand for TREM-1

Christine B. Read, Joseph L. Kuijper, Siv A. Hjorth, Mark D. Heipel, Xiaoting Tang, Andrew J. Fleetwood, Jeffrey L. Dantzler, Susanne N. Grell, Jesper Kastrup, Camilla Wang, Cameron S. Brandt, Anker J. Hansen, Nicolai R. Wagtmann, Wenfeng Xu and Vibeke W. Stennicke

_J Immunol_ 2015; 194:1417-1421; Prepublished online 16 January 2015; doi: 10.4049/jimmunol.1402303

http://www.jimmunol.org/content/194/4/1417

References

This article cites 16 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/194/4/1417.full#ref-list-1

Subscription

Information about subscribing to _The Journal of Immunology_ is online at: http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Author Choice

Freely available online through _The Journal of Immunology_ Author Choice option

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Triggering receptor expressed on myeloid cells (TREM)-1 is an orphan receptor implicated in innate immune activation. Inhibition of TREM-1 reduces sepsis in mouse models, suggesting a role for it in immune responses triggered by bacteria. However, the absence of an identified ligand has hampered a full understanding of TREM-1 function. We identified complexes between peptidoglycan recognition protein 1 (PGLYRP1) and bacterially derived peptidoglycan that constitute a potent ligand capable of binding TREM-1 and inducing known TREM-1 functions. Interestingly, multimerization of PGLYRP1 bypassed the need for peptidoglycan in TREM-1 activation, demonstrating that the PGLYRP1/TREM-1 axis can be activated in the absence of bacterial products. The role for PGLYRP1 as a TREM-1 activator provides a new mechanism by which bacteria can trigger myeloid cells, linking two known, but previously unrelated, pathways in innate immunity. The Journal of Immunology, 2015, 194: 1417–1421.

In this article, we describe the identification of peptidoglycan (PGN) recognition protein 1 (PGLYRP1) as a ligand for TREM-1. When multimerized or complexed with PGN, PGLYRP1 is able to activate TREM-1 and enhance cytokine production in human neutrophils and macrophages.

**Materials and Methods**

**Abs and other reagents**

Anti–TREM-1 (MAB1278), anti-PGLYRP1 polyclonal Ab, and isotype controls were from R&D Systems. Anti–TREM-1 (clone 9E2) (1) was purified from hybridoma supernatant. Anti-PGLYRP1 mAb was generated by immunizing mice with full-length human PGLYRP1. Anti-PGLYRP1 and anti-TNF (as isotype-matched control) were recombinantly expressed as human (h) IgG4 chimeric mAbs.

TREM-1–Fc, TREM-1 tetramer, and CD83 tetramer constructs, consisting of a CD33 leader peptide, followed by the extracellular domain of the corresponding protein (tandem domains for tetramers) fused to a mutated hIgG1 Fc with reduced Fc effector function (E216G, C220S, L234A, L235E, G237A, A330S, P331S), were expressed and purified from HEK293-6E cells. Recombinant hPGLYRP1 was purchased from R&D Systems or made at Novo Nordisk. No major differences in potency were observed when comparing different sources of PGLYRP1. The following TLR ligands (TLRLs) were used: LPS, polyinosinic-polycytidylic acid (both from Sigma-Aldrich), PGN-SA, PGN-BS, PGN-ECndi, PGN-ECnds, FSL-1, Tri-DAP, M-TriDAP, and muramyl dipeptide (MDP) (all from InvivoGen). Lysozyme and mutanolysin were from Sigma-Aldrich. hM-CSF and hIL-4 were expressed and purified from *Escherichia coli*. All proteins were tested for endotoxins using the Limulus amebocyte lysate assay and confirmed to contain <1 EU/mg endotoxin.

**Cells and cell lines**

The BWZ.36 TREM-1 reporter cell line was derived from BWZ.36 cells, which express an NFAT-driven LacZ reporter (5), by transfection with hTREM-1 and hDAP12. LacZ activation was measured using the Beta-Glo kit (Promega). Stimulation with 10 ng/ml PMA + 1 μM thapsigargin (both from Sigma-Aldrich) confirmed a functional NFAT reporter. For coculture stimulations, freshly purified human neutrophils were incubated overnight with the indicated stimulants before adding the TREM-1 reporter cells. HEK293-6E cells expressing a membrane-bound PGLYRP1 were generated by transient transfection with a construct encoding PGLYRP1 fused to the intracellular and transmembrane domain of the type II receptor MDR1 and with DAP12 (Fig. 3B). In Fig. 2B, the charged lysine residue in the transmembrane domain was changed to leucine to eliminate the need for DAP12 cotransfection. Binding of TREM-1–Fc to PGLYRP1 cells was analyzed by flow cytometry, using anti-human IgG-Fc as secondary Ab (Jackson Immuno-Research) and gating on live cells.
Primary human cells were purified from whole blood (Danish Blood Donor Core [Ethical approval no. H.D-2007-0055] or Astarte Biologics), from buffy coats (Danish Blood Donor Core [Ethical approval no. H-D-2008-113]), or from leukopheresis (Research Blood Components).

**Cellular assays**

Primary neutrophils were purified by centrifugation on Ficoll-Paque (Pharmacia), followed by sedimentation in 4% dextran (Sigma-Aldrich). Remaining erythrocytes were lysed using 0.2% NaCl. TLRLs were used at 10 μg/ml (PGN-SA, FSL-1, TriDAP, MDP, M-TriDAP), 1 μg/ml (polyinosinic-polycytidylic acid), or 100 ng/ml (LPS). After overnight culture, supernatants were analyzed for IL-8 using BioPlex (Bio-Rad) or ELISA (R&D Systems). All monocyte/macrophage samples. Data are representative of mean ± 6 SD of triplicate samples. Shown is one experiment out of two

**Surface plasmon resonance analysis**

Assays were run in 1 × HBS-P, 25˚C, at 20–30 μl/min on a Biacore T200 (GE Healthcare). TREM-1 tetramer (4641.1 RU) was coupled to a CM5 chip, and 150 nM PGLYRP1 was injected over the surface in the presence or absence of 10 μg/ml PGN-ECnps. As a negative control for nonspecific binding, a neutralized CM5 surface was run in parallel with the injected reagents and was subtracted to obtain the depicted binding data.

**Results and Discussion**

PGN-stimulated neutrophils activate TREM-1 via PGLYRP1

An endogenous ligand for TREM-1 was suggested to exist on neutrophils activated by bacteria or TLRLs (8). Extending this work, we tested TLRL-stimulated human neutrophils for their ability to activate a TREM-1–expressing reporter cell line. As shown in Fig. 1A, neutrophils stimulated with a TLRL mixture triggered TREM-1 to a similar extent as did an agonistic anti-TREM-1 mAb, whereas stimulation with only TLRL did not induce TREM-1 activation. The neutrophil-induced activity was specific to TREM-1 because it could be blocked by both TREM-1–Fc fusion protein and the anti–TREM-1 mAb 9E2. Although this anti–TREM-1 mAb was used previously by other
Investigators as a pb Ab to stimulate TREM-1 (1), we consistently find that it behaves as an antagonist when soluble. Among the components in the TLRL mixture, only PGN induced the neutrophil-mediated stimulation of TREM-1 (Fig. 1B), whereas other TLR or NOD1/2 ligands were ineffective (Fig. 1C). This suggested that the role of PGN in neutrophil-mediated TREM-1 activation was not simply a requirement for concurrent TLR2/NOD1/2 stimulation but specifically supported ligand induction or function.

To identify the putative neutrophil-expressed TREM-1 ligand, soluble TREM-1 or a control protein were cross-linked to neutrophils cultured with PGN. Resulting complexes were isolated by immunoprecipitation and identified by mass spectrometry in two independent experiments (XL IPMS) to contain PGLYRP1 peptides (Fig. 1D). In line with this, an anti-PGLYRP1 Ab could specifically block the neutrophil-mediated activation of the TREM-1 reporter cell line (Fig. 1E), supporting the conclusion that PGLYRP1 is the TREM-1–stimulating protein on neutrophils.

PGLYRP1 forms a TREM-1 ligand complex with PGN

PGLYRP1 is an antibacterial protein found in neutrophil tertiary granules, and it belongs to a family of PGN-binding proteins (PGRPs) that is highly conserved among insects and mammals (9). In Drosophila, PGRPs function as pattern-recognition proteins that bind bacterial PGN and activate Toll and Imd pathways to initiate immune responses (10). Mammalian PGRPs have primarily been described as effector molecules with direct bactericidal activity (9). Although PGLYRP1 was reported to be involved in neutrophil production of reactive oxygen species (11), as well as modulation of immune responses in vivo (12), the underlying mechanism has remained undefined. Using TREM-1 reporter cells we found that soluble PGLYRP1 could stimulate TREM-1, but only in the presence of PGN (Fig. 1F), and this could be blocked by anti–TREM-1 (Fig. 1G). This suggests that neutrophil-released PGLYRP1, when present with PGN, constitutes a functional ligand for TREM-1.

PGN is a macromolecular component in the cell wall of all bacteria and is known to bind PGLYRP1 (13). Most myeloid cells express the PGN-sensing receptors TLR2 and NOD1/2. Although TREM-1 does not bind bacterial components directly (4), our findings suggest that TREM-1 is a bacteria-sensing receptor on myeloid cells, exploiting PGLYRP1 for specific recognition of PGN. Thus, the presence of PGLYRP1 can regulate whether PGN is able to induce TREM-1 activation. In support of this, we found that the addition of PGLYRP1 to PGN-stimulated primary human macrophages increased TNF-α secretion >7-fold; notably, this response was blocked by anti–TREM-1 (Fig. 1H).

Neutrophils, like macrophages, express both TLRs and TREM-1. When neutrophils degranulate upon stimulation, granule proteins, such as PGLYRP1, are released (11). We hypothesized that PGLYRP1 released by PGN-stimulated...
neutrophils binds PGN to form ligand complexes capable of activating adjacent TREM-1–expressing cells, thus enhancing the response. Indeed, when we examined IL-8 responses from PGN-stimulated neutrophils, blockade of either TREM-1 (Fig. 1I) or PGLYRP1 (Fig. 1J) partially inhibited IL-8 release, confirming a contribution of both PGLYRP1 and TREM-1 to PGN-induced responses in neutrophils. The finding that PGLYRP1 combined with PGN triggers TREM-1 provides a novel mechanism for how bacteria induce TREM-1 activation, and it may provide an explanation for why TREM-1 blockade reduces mortality in mouse models of sepsis (3).

**Multimeric PGN is required for PGN-PGLYRP1–mediated TREM-1 activation**

To further investigate the role of PGN in PGLYRP1–mediated TREM-1 activation, we examined the interaction of PGN, TREM-1, and PGLYRP1. Using surface plasmon resonance analysis, we found that PGLYRP1 bound transiently to immobilized TREM-1 (Fig. 2A). Interestingly, despite PGN being critical for soluble PGLYRP1 activating TREM-1 (Fig. 1F), PGN only had a stabilizing effect, and it was not essential for the interaction (Fig. 2A). This PGN independence was confirmed using flow cytometry, showing TREM-1–Fc binding to HEK293 cells expressing a membrane-bound PGLYRP1 but not to mock-transfected cells (Fig. 2B). Thus, PGLYRP1 and TREM-1 can bind each other, and although PGN can enhance the binding, it is not essential for the interaction. No direct binding of PGN to TREM-1 was observed (data not shown), arguing against PGN being a direct ligand for TREM-1.

Because PGN is a complex macromolecule, we hypothesized that PGLYRP1 might require multimerization to stimulate TREM-1 and that PGN functions as a scaffold enabling this. To address this, we tested enzymatically digested PGN together with PGLYRP1 in the reporter cell assay. In agreement with the hypothesis, the ability of PGN to support PGLYRP1–mediated TREM-1 activation was eliminated by mutanolysin treatment, which fully degrades both *E. coli*–derived PGN (PGN-Ecndi) and *Staphylococcus aureus*–derived PGN (PGN-SA), whereas lysozyme treatment results in full degradation of PGN-Ecndi but not PGN-SA (Fig. 2C, 2D) (14). Furthermore, the PGN subunit MDP could not substitute for PGN in PGLYRP1-mediated TREM-1 activation (data not shown). Lysozyme digestion consistently increased the PGN-SA–mediated PGLYRP1–TREM-1 signal (Fig. 2C). Although not fully understood, we observed that fractionation of PGN species by size impacts the ability of the PGN to support PGLYRP1–TREM-1 activation (data not shown). Lysozyme may result in a partial digestion of PGN-SA, thus affecting the signaling strength.

**PGLYRP1 alone can stimulate TREM-1 on myeloid cells**

To further address the role of PGN during PGLYRP1–mediated TREM-1 signaling, we constructed different multimeric formats of PGLYRP1. We found that pb PGLYRP1 alone (Fig. 3A), as well as HEK293 cells expressing PGLYRP1 on the cell surface (Fig. 3B), was able to activate TREM-1. Thus, although stimulation with soluble PGLYRP1 alone did not induce a signal (Fig. 1F), PGLYRP1 presented in either a pb form or anchored to a cell surface was a potent stimulant of TREM-1.

As seen with TREM-1 reporter cells, human macrophages responded to pb PGLYRP1 in a TREM-1–dependent manner (Fig. 3C), although the response was lower than the one to PGN plus PGLYRP1 (Fig. 1H). The lower response most likely reflects the synergy between TREM-1 and a concurrent TLR stimulation (1, 2), but it also may be caused by differences in the PGLYRP1–TREM-1 interaction when artificially immobilizing PGLYRP1 on a plastic surface. Human neutrophils stimulated with pb PGLYRP1 produced both IL-8 (Fig. 3D) and superoxide (data not shown), consistent with published data using pb agonistic anti–TREM-1 (2). PGLYRP1–induced responses in both macrophages and neutrophils could be inhibited with the anti–TREM-1 mAb, confirming the role of TREM-1 (Fig. 3C, 3D). Taken together, these data support the hypothesis that multimeric presentation of PGLYRP1 is sufficient for TREM-1 activation in myeloid cells and raise the possibility that TREM-1 activation also occurs in the absence of infections.

In conclusion, we present strong evidence that PGLYRP1 is a functional ligand for TREM-1. PGLYRP1 is a well-known neutrophil granule protein with antibacterial properties (9) that is present at readily detectable levels in plasma from healthy individuals (15) (data not shown). Our results show that PGLYRP1 must be multimerized to become a functional TREM-1 ligand. This can be achieved in the presence of PGN, thus providing a likely explanation for how TREM-1 activation is induced during bacterial infection. The need for cross-linking of PGLYRP1 also could be a safeguard ensuring that TREM-1 on circulating myeloid cells is not inappropriateially stimulated. Interestingly, PGLYRP1 was shown to be present in neutrophil extracellular traps (16), suggesting another potential mechanism for PGLYRP1 multimerization and TREM-1 activation and opening new areas of research into the role of TREM-1 in disease.

**Acknowledgments**

We thank L. Madsen, B. Davidsen, B. Breuning, B. Stegmann, P. Binn, C. Wiberg, N. Rasmussen, T.-Y. Chao, Y. Luo, Z. Yang, T. Dong, Z. Guan, C. Hauskins, and A. Yabannavar for technical expertise and protein production. We also thank B. Ursø, F. Ramsdell, J. Peschon, P. Kong, H. Stennicke, and S. Read for discussions and scientific input during this work.

**Disclosures**

The findings described in this article are part of a patent application submitted by Novo Nordisk A/S. All authors are or have been employed by Novo Nordisk A/S.

**References**


